New hope for Tough-to-Treat lymphoma: experimental drug added to standard chemo
NCT ID NCT06947967
Summary
This study is testing if adding an experimental drug called tucidinostat to standard CHOP chemotherapy works better than CHOP alone for adults newly diagnosed with a specific type of rare T-cell lymphoma. The main goal is to see if the combination helps keep the cancer from growing or coming back for a longer period. About 224 participants will be randomly assigned to receive either the real combination or CHOP with a placebo pill.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, T-CELL, PERIPHERAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.